{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:16:52Z","timestamp":1790885812084,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18lk0201083h0003"],"award-info":[{"award-number":["JP18lk0201083h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eclinm.2022.101707","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:01:17Z","timestamp":1666728077000},"page":"101707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Keiko","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuishin","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Hanajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ayaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-7863","authenticated-orcid":false,"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-1579","authenticated-orcid":false,"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hirohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutsugu","family":"Tatebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eclinm.2022.101707_bib1","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1007\/s12035-017-0856-0","article-title":"Causative genes\u00a0in\u00a0amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration","volume":"55","author":"Maurel","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101707_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A\u00a0controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101707_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101707_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101707_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","article-title":"Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons","volume":"7","author":"Wainger","year":"2014","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.stemcr.2018.11.021","article-title":"Neurite collapse and altered ER Ca(2+) control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation","volume":"12","author":"Korecka","year":"2019","journal-title":"Stem Cell Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101707_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.stemcr.2021.02.004","article-title":"Altered neuronal support and inflammatory response in bipolar disorder patient-derived astrocytes","volume":"16","author":"Vadodaria","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101707_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","article-title":"iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders","volume":"29","author":"Okano","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"391","key":"10.1016\/j.eclinm.2022.101707_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101707_bib12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s12185-022-03314-y","article-title":"Safety profile of bosutinib\u00a0in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis","volume":"115","author":"Takahashi","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-020-02878-x","article-title":"Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"112","author":"Hino","year":"2020","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/146608299300079484","article-title":"Gastrointestinal dysfunction in amyotrophic lateral sclerosis","volume":"1","author":"Toepfer","year":"1999","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101707_bib15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archneurol.2012.254","article-title":"Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review","volume":"69","author":"Costa","year":"2012","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101707_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033131","article-title":"Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients","volume":"9","author":"Imamura","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2022.101707_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3389\/fneur.2020.00919","article-title":"CSF neurofilament light chain elevation\u00a0predicts ALS severity and progression","volume":"11","author":"Sun","year":"2020","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101707_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","article-title":"Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS","volume":"88","author":"Shepheard","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101707_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/jnnp-2019-321916","article-title":"Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes","volume":"91","author":"Vu","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101707_bib20","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","article-title":"Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study","volume":"71","author":"Chi\u00f2","year":"2014","journal-title":"JAMA Neurol"},{"issue":"22","key":"10.1016\/j.eclinm.2022.101707_bib21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eclinm.2022.101707_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.712245","article-title":"Role of blood neurofilaments in the prognosis of amyotrophic lateral sclerosis: a meta-analysis","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101707_bib23","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/ana.26047","article-title":"Prediction model of amyotrophic lateral sclerosis by deep learning with patient induced pluripotent stem cells","volume":"89","author":"Imamura","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101707_bib24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/brain\/awaa022","article-title":"The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications","volume":"143","author":"Guo","year":"2020","journal-title":"Brain"},{"issue":"1-2","key":"10.1016\/j.eclinm.2022.101707_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101707_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046185","article-title":"c-Abl inhibition delays\u00a0motor neuron degeneration in the G93A mouse, an animal\u00a0model of amyotrophic lateral sclerosis","volume":"7","author":"Katsumata","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.eclinm.2022.101707_bib27","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1093\/hmg\/ddu211","article-title":"Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice","volume":"23","author":"Wenqiang","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"Pt 10","key":"10.1016\/j.eclinm.2022.101707_bib28","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/brain\/awn161","article-title":"Suicide among patients\u00a0with amyotrophic lateral sclerosis","volume":"131","author":"Fang","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","article-title":"Fluid-based biomarkers for amyotrophic lateral sclerosis","volume":"14","author":"Vu","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101707_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.0000000000007695","article-title":"ALS drug development guidances and trial guidelines: consensus and opportunities for alignment","volume":"93","author":"Andrews","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101707_bib31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101707_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41593-021-01006-0","article-title":"Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines","volume":"25","author":"Baxi","year":"2022","journal-title":"Nat Neurosci"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101707_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/jnnp-2015-311541","article-title":"A\u00a0rapid functional decline type of amyotrophic lateral sclerosis is linked to low\u00a0expression of TTN","volume":"87","author":"Watanabe","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101707_bib34","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2589-7500(21)00274-0","article-title":"Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study","volume":"4","author":"Faghri","year":"2022","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1474-4422(21)00420-8","article-title":"Major research advances in amyotrophic lateral sclerosis in 2021","volume":"21","author":"Petri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib36","doi-asserted-by":"crossref","first-page":"fcac029","DOI":"10.1093\/braincomms\/fcac029","article-title":"Multicentre appraisal of\u00a0amyotrophic lateral sclerosis biofluid biomarkers shows primacy\u00a0of blood neurofilament light chain","volume":"4","author":"Thompson","year":"2022","journal-title":"Brain Commun"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101707_bib37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn.2778","article-title":"Characterizing the RNA targets and position-dependent splicing regulation by TDP-43","volume":"14","author":"Tollervey","year":"2011","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101707_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12929-020-00628-z","article-title":"Functional roles of long non-coding RNAs in motor neuron development and disease","volume":"27","author":"Chen","year":"2020","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.eclinm.2022.101707_bib39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2741\/4777","article-title":"Cancer-related genes and ALS","volume":"24","author":"Yamamoto","year":"2019","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101707_bib40","doi-asserted-by":"crossref","first-page":"1778.e9","DOI":"10.1016\/j.neurobiolaging.2014.01.014","article-title":"Genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations","volume":"35","author":"Xie","year":"2014","journal-title":"Neurobiol Aging"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022004370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022004370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:22:46Z","timestamp":1781817766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022004370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":40,"alternative-id":["S2589537022004370"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101707","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101707"}}